Perspective Therapeutics (FRA:AAJ0) Shareholder Yield % : -48.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
33 GF Score
Price €2.46
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Shareholder Yield %?

Perspective Therapeutics FRA:AAJ0 -9.08% 33 Shareholder Yield % is -48.00% as of Mar. 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Perspective Therapeutics ranks worse than 93.76% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Perspective Therapeutics's Shareholder Yield % was -48.00%.


Perspective Therapeutics  (FRA:AAJ0) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Perspective Therapeutics Shareholder Yield % Related Terms


Perspective Therapeutics Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Shareholder Yield % Chart

Perspective Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.28 -56.46 0.56 -2.22 -128.33

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.71 -4.21 -3.83 -4.74 -34.42

FRA:AAJ0 vs ELMD, MASS, CV: Shareholder Yield % Comparison

For the Medical Devices subindustry, Perspective Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perspective Therapeutics Shareholder Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Shareholder Yield % falls into.


FRA:AAJ0
33GF Score
Perspective Therapeutics Inc FRA:AAJ0
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Shareholder Yield % Calculation

Perspective Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-34.51 %+0.17 %
=-34.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -48.00% mean?
Perspective Therapeutics (FRA:AAJ0) has a Shareholder Yield % of -48.00% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Perspective Therapeutics and its competitors. According to the industry distribution chart, Perspective Therapeutics ranks #766 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 93.8%.
Is Perspective Therapeutics' Shareholder Yield % too high?
Perspective Therapeutics' current Shareholder Yield % is -48.00%. Based on the distribution chart, Perspective Therapeutics ranks #766 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Shareholder Yield % compare to ELMD and MASS?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #766 out of 817 companies for Shareholder Yield %. This places Perspective Therapeutics in the lower half of its industry. The industry median Shareholder Yield % is 0.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Devices & Instruments company?
The median Shareholder Yield % among Medical Devices & Instruments companies is 0.14, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Perspective Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Shareholder Yield % is 0.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perspective Therapeutics's current Shareholder Yield % is -48.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current Shareholder Yield % of -48.00%. The current Shareholder Yield % is -48.00%. Perspective Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current Shareholder Yield % is -48.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
33GF Score

Get the complete analysis for FRA:AAJ0

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.46
Price